Abstract: To explore the effects of Liposomal Prostaglandin E1(Lipo-PGE₁) on the blood system in patients with cardiopulmonary bypass(CPB). Methods20 patients received cardiac valve replacement undergoing CPB were randomly divided into two groups (10 patients in each group): the experimental group and the control group. In the experimental group, patients were administered 3ng／(kg·min) Lipo-PGE1and Lipo-PGE₁ which was added into the priming solution (5ng／mL) of the extracorporeal circulation machine. In the control group, patients were administered the same volume of normal saline. The levels of thromboxane B₂(TXB₂), 6-keto-Prostaglandin F1α(6-Keto-PGF1α) and free hemoglobin (F-HB) in the plasma were determined five times around CPB. ResultsIn the two groups, levels of TXB₂, 6-Keto-PGF1α and F-HB were all obviously increased in CPB and they reached the highest when CPB stopped. The level of 6-Keto-PGF1α in the experimental group was significantly higher than that in the control group, while levels of TXB₂, TXB2／6Keto-PGF1αand F-HB were significantly lower than those in the control group (P<0。05). Conclusion LipoPGE1 can reclaim the imbalance of TXA2／PGI2 in CPB and partly improves coagulation disorder and lessens hemolysis caused by CPB, so it can obviously reduce kidney injury.

Key words: Prostaglandin E₁, Liposome diluent, Cardiopulmonary bypass, Blood system